InterMune (FRA:IUX) Days Inventory : 173.53 (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is InterMune Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). InterMune's Average Total Inventories for the three months ended in Jun. 2014 was €8.08 Mil. InterMune's Cost of Goods Sold for the three months ended in Jun. 2014 was €4.25 Mil. Hence, InterMune's Days Inventory for the three months ended in Jun. 2014 was 173.53.

The historical rank and industry rank for InterMune's Days Inventory or its related term are showing as below:

FRA:IUX' s Days Inventory Range Over the Past 10 Years
Min: 49.87 Med: 146.44 Max: 956.76
Current: 256.67

During the past 13 years, InterMune's highest Days Inventory was 956.76. The lowest was 49.87. And the median was 146.44.

FRA:IUX's Days Inventory is not ranked
in the Biotechnology industry.
Industry Median: 199.78 vs FRA:IUX: 256.67

InterMune's Days Inventory declined from Jun. 2013 (474.43) to Jun. 2014 (173.53).

Inventory Turnover measures how fast the company turns over its inventory within a year. InterMune's Inventory Turnover for the three months ended in Jun. 2014 was 0.53.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InterMune's Inventory-to-Revenue for the three months ended in Jun. 2014 was 0.31.

InterMune Days Inventory Historical Data

The historical data trend for InterMune's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Days Inventory Chart

InterMune Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Days Inventory

Get a 7-Day Free Trial

102.20

956.42

332.07

378.55

InterMune Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Days Inventory	Get a 7-Day Free Trial															474.43	337.01	298.98	303.49	173.53

Competitive Comparison of InterMune's Days Inventory

For the Biotechnology subindustry, InterMune's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Days Inventory distribution charts can be found below:

* The bar in red indicates where InterMune's Days Inventory falls into.

InterMune Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

InterMune's Days Inventory for the fiscal year that ended in Dec. 2013 is calculated as

	Days Inventory (A: Dec. 2013 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2012 )	+	Total Inventories (A: Dec. 2013 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2013 )	*	Days in Period
=	( (7.635	+	8.121)	/	2 )	/	7.596	*	365
=	7.878					/	7.596	*	365
=	378.55

InterMune's Days Inventory for the quarter that ended in Jun. 2014 is calculated as:

	Days Inventory (Q: Jun. 2014 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Mar. 2014 )	+	Total Inventories (Q: Jun. 2014 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2014 )	*	Days in Period
=	( (8.063	+	8.09)	/	2 )	/	4.247	*	365 / 4
=	8.0765					/	4.247	*	365 / 4
=	173.53

InterMune (FRA:IUX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

InterMune's Inventory Turnover for the three months ended in Jun. 2014 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	4.247	/	8.0765
	=	0.53

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

InterMune's Inventory to Revenue for the three months ended in Jun. 2014 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	8.0765	/	26.304
	=	0.31

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

InterMune Days Inventory Related Terms

Thank you for viewing the detailed overview of InterMune's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune Headlines

No Headlines